QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND – Press Release

CAMBRIDGE, Mass.–(Business Wire)–QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced that the company will present two posters featuring data from two of the company’s preclinical precision medicine ALS programs at the Motor Neuron Disease Association (MNDA) 31st International Symposium on ALS/MND, being held virtually on December 9-11, 2020.

QurAlis co-founders and Harvard professors Kevin Eggan, Ph.D. and Clifford Woolf, M.D., Ph.D., members of the QurAlis Scientific and Clinical Advisory Boards, Brian Wainger, M.D., Ph.D. (Massachusetts General Hospital) and Merit Cudkowicz, M.D., M.Sc. (Massachusetts General Hospital), and other authors recently published in JAMA Neurology the results of a clinical study investigating the therapeutic potential of Kv7 agonism in ALS. The clinical data support QurAlis’ belief that a safe Kv7 opener could be an effective disease-modifying therapy for ALS patients with motor system hyperexcitability, an approach that QurAlis is pursing with its preclinical program investigating the regulation of the Kv7.2/7.3 ion channel.

The poster presentations will share, for the first time publicly, results from preclinical studies of QurAlis’ program investigating a novel Kv7.2/7.3 ion channel agonist as a potential treatment for motor neuron hyperexcitability and excitotoxicity, as well as its program targeting the TBK1 autophagy pathway.

“While KV7 agonists have shown great potential as a treatment for the 20-50% of ALS patients who present with hyperexcitability in their motor system, they can often cause undesired side effects such as dizziness and fatigue,” said Daniel Elbaum, Ph.D., Chief Scientific Officer of QurAlis. “The preclinical data we will be presenting show that the improved channel specificity of our novel Kv7.2/7.3 agonist could translate into an improved clinical safety profile with significant reduction in off-target adverse events. We look forward to sharing the full results of this preclinical study as well as discussing our autophagy program at the MNDA 31st International Symposium on ALS/MND.”

Details of the presentations are as follows:

Title: TBK1 Autophagy Pathway Disease Mechanisms in ALS

Authors: Erika Norabuena; Clinton Bourbonais; Kasper Roet, Ph.D.; Kevin Eggan, Ph.D.; Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.

Presenting Author: Erika Norabuena

Date/Time: December 9, 2020, 12:10pm-12:50pm ET

Poster/Abstract Number: TST-07

Link to abstract

Title: QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients

Authors: Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.; Kasper Roet, Ph.D.

Presenting Author: Daniel Elbaum, Ph.D.

Date/Time: December 11, 2020, 7:05am-7:50am ET

Poster/Abstract Number: TST-20

Link to abstract

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. ALS breaks down nerve cells, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Its average life expectancy is three years, and there is currently no cure for the disease.

About QurAlis Corporation

QurAlis is bringing hope to the

Read more

Farmmi Participates in Shanghai International Health, Wellness and Fitness Expo

LISHUI, China, Nov. 30, 2020 /PRNewswire/ — Farmmi, Inc. (“Farmmi” or the “Company”) (NASDAQ: FAMI), an agriculture products supplier in China, today announced its participation in the Shanghai International Health, Wellness and Fitness Expo (the “Expo”), which was held from November 25 to 27, 2020. The Expo, the largest of its kind in Asia, included edible fungi in its featured products.

The Expo covered a total exhibition area of 54,000 square meters, with 452 national and international brands, gathering 43,076 domestic and international buyers.

Ms. Yefang Zhang, Farmmi’s Chairwoman and CEO, commented, “While we have done an excellent job closing sales opportunities in the new virtual world of 2020, it was exciting for us to get back in front of customers and partners at the Expo. The organizers put necessary safety controls in place to ensure the health of attendees. We thank them for their efforts in making this such a successful expo for all participants.”

“With the improvement of living standards, people are becoming more particular about their health and diet. Farmmi is benefitting from inclusion and wider adoption of edible fungi, which are now a standard part of the new healthy diet structure. Low calorie bacteria with high protein, low fat and high efficacy are now recognized worldwide as nutritional, health foods,” continued Ms. Zhang. “As a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products, Farmmi has the scale and strict controls to build upon customer demand growth worldwide.”

Ms. Zhang concluded, “The Expo, which emphasized technology and innovation, served as an important platform for our company to meet customers, promote products, carry out industry exchanges and seek cooperation opportunities. This is fully in-line with our strategy to seek out and execute on increased business opportunities in both the domestic China market and worldwide.”

About Farmmi, Inc.

Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products. The Company’s Farmmi Liangpin Market serves as a trading platform for Chinese geographical indication agricultural products and is a large platform for consumers to access locally sourced agricultural products. For further information about the Company, please visit: http://ir.farmmi.com.cn/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including the potential impact of COVID-19 on our business within and outside of China. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”

Read more

Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial

Amgen and Eisai to Participate in the Immune Modulation Domain of REMAP-COVID, an Adaptive Clinical Trial to Test Interventions for Patients Hospitalized With COVID-19

Amgen’s Apremilast and Eisai’s Eritoran to Be Evaluated Across Multiple International Trial Sites Within the REMAP Network

Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA), and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) — The Global Coalition for Adaptive Research (GCAR) in collaboration with Amgen and Eisai Co., Ltd., today announced enrollment of the first patient in the immune modulation domain of REMAP-COVID, a sub-study of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. Amgen’s apremilast and Eisai’s investigational eritoran are being evaluated as potential therapeutic agents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005657/en/

REMAP-CAP was developed to test treatments for severe pneumonia both in non-pandemic and pandemic settings. In February 2020, REMAP-CAP rapidly pivoted to its pandemic mode (the REMAP-COVID sub-study), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. This trial is a multicenter, randomized platform study, with treatments tested within groupings or “domains” based on pathway or mechanism of action.

The trial is being conducted in the multi-hospital UPMC (University of Pittsburgh Medical Center) health system along with over 20 hospitals in the United States. Additional global sites across the trial network will follow. University of Pittsburgh is serving as the U.S. Regional Coordinating Center.

“Partnering with the biopharmaceutical industry to be able to efficiently test well-understood targeted agents is critical to understanding treatment paradigms for COVID-19 patients,” says Derek Angus, MD, MPH, FRCP, U.S. Principal Investigator of REMAP and Chief Healthcare Innovation Officer, UPMC Health System. “Today’s announcement marks an important milestone in the collaboration between industry and the scientific and academic community to work collectively to evaluate potentially promising therapies to support patients hospitalized with COVID-19.”

Amgen’s apremilast is an oral drug which inhibits the activity of PDE4 (Phosphodiesterase 4), an enzyme found in inflammatory cells in the human body. By inhibiting PDE4, apremilast is thought to modulate the production of inflammatory cytokines and other mediators, which may prove helpful in inhibiting the inflammatory response associated with the signs, symptoms and pulmonary involvements observed in some COVID-19 patients. Apremilast is currently approved for use in more than 45 countries as an oral treatment for inflammatory diseases including moderate to severe plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behcet’s disease.

“Amgen believes that, based on its mechanism of action, apremilast might help prevent the respiratory distress seen in moderate to severe-stage adult COVID-19 patients,” said David M. Reese, M.D., Executive Vice President of Research and Development at Amgen. “We are proud to be joining REMAP-COVID, which is an important and innovative effort utilizing a platform approach and has the potential to rapidly identify whether apremilast

Read more

On International Pronouns Day, transgender women talk inner strength, outer beauty

Wednesday marked the third annual International Pronouns Day, which is meant to educate and raise awareness about the importance of respecting personal pronouns.

This day, and the push to make asking and using other people’s personal pronouns commonplace, spotlights an issue that particularly affects the transgender and gender nonconforming communities, experts have said.

Two transgender women and a Northwell Health surgeon spoke at a livestreamed event organized by the hospital on Wednesday about some of the issues facing the transgender community.

Rubi Lacroix, 25, of Babylon, who grew up in Gramercy Park, and Demi Washington, 28, a South Carolina native who now lives in Brooklyn, underwent facial feminization surgery and spoke about their experiences alongside Dr. James Bradley.

The operations last seven hours or so as chins and jaws are softened, noses and brows re-sculpted and hairlines lowered, experts said.

“I have a softer face now,” Washington said. “It is easier for people to see me as a woman.”

Said Lacroix, on her way to becoming an X-ray technician and then a nurse: “It was really tough; I had to do this.”

About one half of transgender boys attempted suicide in their teens; for girls the rate was nearly one-third and for nonbinary individuals, whose identities fall outside of the gender binary, the figure was just under 42%, an October 2018 American Academy of Pediatrics study found.

“This is not about hair and makeup … this is a life-changing procedure not easily recovered from,” Washington said.

During the recovery, said Washington, “There is a lot of time to think about what it means to have the exterior features of a woman. This doesn’t erase anybody’s strife — now, all of a sudden you’re thoroughly deemed a sexual being. Now I’m reduced to the exterior, the woman you happen to see.”

“You have to be very strong to (handle) the transitions,” Washington added.

Crimes against transgender individuals appear to be on the rise by some measures, though they likely are quite undercounted because people are wary of how they will be treated — and some are not out.

Two years ago, 10 hate crimes against transgender individuals or their property were reported in New York State, down from 14 in 2017, Division of Criminal Justice Services statistics show. There were 18 such hate crimes in 2016, and one in 2014 and 2015.

For nonbinary individuals, who may prefer to be addressed with plural pronouns instead of as “he” or “she,” there were four hate crimes reported in 2018, zero in 2017, and five in 2016. Two were tracked in 2015, three in 2014.

Like many transgender individuals, Lacroix knew early on that her body did not match who she was on the inside.

“I think this is the best decision I ever made in my life,” she said. “Now, people

Read more

Applications For International Dentists

Palm Beach Smiles – Cosmetic Dentistry & six Month Braces This weblog is a supply of present data about cosmetic dentistry written by Dr. Michael Barr, Boynton Beach dentist and founder of Palm Beach Smiles. Le cabinet dentaire des Docteurs CHEKIR-KASTALLI et TELLISSI vous accueille sur rendez-vous, du lundi au vendredi de 9h10 à 19h. Il pose des prothèses dentaires totales ou partielles comme les bridges, couronnes, dents sur pivot. Our philosophy is to supply, in a single single location, all dental knowledge provided by exclusive practitioners in their field of experience.

L’article 95..1 du Code des professions ( chapitre C-26 ) s’applique au règlement pris en application du premier alinéa. Cosmetic dentists aid individuals really feel much more confident about them, which is some thing each and every dentist must pride themselves on.

Le dentiste ne va pas souvent vous le dire, mais se brosser les dents trois fois par jour n’est pas forcément très utile. Cette formation de deux ans lui a permis de mieux comprendre les besoins spéciaux de ses individuals et de s’y adapter judicieusement, en particulier ceux des personnes âgées ou ayant des problèmes de santé complexes.

Parfois le problème vient simplement du fait qu’on se rince la bouche après brossage des dents et que ça peut nuire à l’efficacité du dentifrice (focus, pas chez tout le monde, mais juste chez certains.) Bref, c’est souvent du cas par cas, et on ne va pas commencer à dire à tout le monde que le brossage des dents est inutile, puisque c’est faux.

Most dentists are self-employed contractors in basic practice, mixing NHS with private perform, and earn £50,000 to £110,000. From the desk of Dr. Hans Skariah: Dentist at Promenade Court Dental and Plattsville Dental. Some documentation is good for patient security, but some is unrelated to actual care.…

Read more